Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 267

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 267
---
 net         |     |                    |     867 |   |     |      |   1,547 |   |     |                   |   3,091 |   |     |      |   4,723 |   |
| Loss before income tax expense      |     |                    | (12,546 | ) |     |      | (16,302 | ) |     |                   | (45,418 | ) |     |      | (49,496 | ) |
| Net loss                            |     | $                  | (12,546 | ) |     | $    | (16,302 | ) |     | $                 | (45,418 | ) |     | $    | (49,496 | ) |

Product Sales, Net Our product sales, net consist of sales of FYARRO since its launch in the United States on February 22, 2022. Product sales, net for the three and nine months ended September 30, 2024 were $7.2 million and $18.7 million, respectively. For the three and nine months ended September 30, 2023, product sales, net were $6.0 million and $18.0 million, respectively. The increase in the three and nine months ended September 30, 2024 compared to the same period in the prior year was primarily due to strong demand. Operating Expenses Selling, General and Administrative Expenses Selling, general and administrative expenses for the three months ended September 30, 2024 and 2023 were $7.2 million and $11.2 million, respectively. The $4.0 million decrease was primarily driven by a reduction of $2.3 million in personnel expenses, $1.5 million in commercial and marketing expenses, and $0.3 million of legal and other expenses, offset by an increase of $0.1 million related to consulting expenses. - 185 -

Selling, general and administrative expenses for the nine months ended September 30, 2024 and 2023 were $25.7 million and $34.2 million, respectively. The $8.5 million decrease was driven by a reduction of $4.0 million in commercial and marketing expenses, $2.3 million in legal and other expenses, $2.1 million in personnel expenses, and $0.1 million of consulting and insurance expenses. Research and Development Expenses The following table presents our research and development expenses for the periods indicated (in thousands):

|